RXi Pharmaceuticals Corp (NASDAQ:RXII) entered into an exclusive option agreement to acquire all outstanding capital stock of MirImmune, Inc. in consideration for a number of shares equal to 19.99% of the then-outstanding shares of common stock of the Company, plus additional potential consideration contingent on MirImmune reaching certain milestones. RXi Pharmaceuticals can exercise the option to acquire MirImmune on the terms set forth in the option agreement at any time prior to April 5, 2017, but has no obligation to do so.